All News
Large data from Japanese Ninja database in abst#0183 shows incidence of malignancies in Japanese RA patients similar to Japanese gen pop. Comparable in patients exposed and unexposed to biologics/JAKs. #ACR20 @RheumNow
Eric Dein ejdein1 ( View Tweet)
15 % of Relapsing Polychondritis meet diagnosis for MAGIC syndrome (Mouth and genital ulcers with inflamed cartilage) - overlap of RP and Behcet's Abst#0425 #ACR20 #ACRbest @RheumNow https://t.co/qaHWwOOL7Q
Bella Mehta bella_mehta ( View Tweet)
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest
Robert B Chao, MD doctorRBC ( View Tweet)
PMR takes fit patients, and drags them down.
In this @HSpecialSurgery cohort, PMR patients were more frail: worse physical function, fatigue, and pain - despite a low comorbidity burden.
We need to understand the burden of PMR better. IL-6?
@SattuiSEMD #ACR20 ABST0422 @RheumNow https://t.co/j6HLNA7ANv
David Liew drdavidliew ( View Tweet)
Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow
k dao KDAO2011 ( View Tweet)
Dr.Gonzalez-Mazon describes surrogate markers assoc'd w #atherosclerosis in #axSpA: BASFI, BASMI, IBD, ESR, CRP, prednisone and DMARDs use. @RheumNow #ACR20 abst#0448 https://t.co/g27qA4qpPL
sheila RHEUMarampa ( View Tweet)
Abst#0135 at #ACR20 illustrates the drivers of patient satisfaction per a survey of 374 U.S. pts. The biggest obstacles to managing RA are pain (80%), fatigue (72%), & depression/anxiety (51%), but only 51% of pts feel that these are addressed. @RheumNow https://t.co/I2ac2T2TOA
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
The GRA now have >17,000 pts registered! Watch the video link @rheumnow or YouTube: https://t.co/tdp5q7tAPK
Please visit the GRA booth @rheum_cat @JYazdanyMD @philipcrobinson @rheum_covid #ACR20 https://t.co/UObvGO3n9Q
Links:
k dao KDAO2011 ( View Tweet)
Agreed- hence the debate is more about patient preference and we need to equip patients with enough information to make correct choices for themselves! @ACRheum @RheumNow #ACR20 https://t.co/zp8HX0YPBV
alexa meara lexmeara ( View Tweet)
Where one lives matters! Especially during the #COVID19 "flares" - Geographical variations in risk perception and medication management by rheumatologists vary by #COVID19 case burden in the community. Check our abst#0005 #ACR20 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
What's your initial biologic of choice when escalating therapy for PsA patients non-responsive to csDMARDs? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
PsA pts have ^ risk of developing polyclonal gammopathy, MGUS, and possibly progression to lymphoproliferative malignancy. #ABS0338 #ACR20 @RheumNow https://t.co/jl6sq1KcKZ https://t.co/BHrGKPXs3a
Dr. Rachel Tate uptoTate ( View Tweet)
#GREATDEBATE Dr. Weinblatt won - but based on the limited # people polled d/t difficulties with website #ACR20 @RheumNow
k dao KDAO2011 ( View Tweet)
Do you screen your PsA patients for lymphoproliferative disease? @RheumNow #ACR20 #ABS0338
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. G Gilkeson #Klempererlecture #ACR20 @rheumnow
There is a lupus gradient b/t Africa and US: we are seeing more SLE in the US (genetics? environmental? diet?)
k dao KDAO2011 ( View Tweet)
The Great Debate results! https://t.co/tJk0yIRqfK
Dr. Rachel Tate uptoTate ( View Tweet)
Since you’ve just listened to The Great Debate, what do you use as your first line therapy in RA #ACR20? @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
MTX & liver fibrosis:
71% pts w/low FIB-4i of<1.45
No correlation bet FIB-4 values & cumulative MTX dose
Cumulative MTX dose not sig. ⬆ in pts with FIB-4i >1.45 @RheumNow #ACR20 Abstr#0205 https://t.co/RmyAz9M5fw
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by BMS, @HorizonNews , @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)